Hans Moebius
Hoofd Techniek/Wetenschap/O&O bij Exciva GmbH
Vermogen: 175 645 $ op 30-04-2024
Actieve functies van Hans Moebius
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Exciva GmbH
Exciva GmbH Miscellaneous Commercial ServicesCommercial Services Exciva GmbH is a clinical stage biopharmaceutical company located in Heidelberg, Germany. Exciva is focused on delivering an innovative treatment to address symptoms of Alzheimer's patients. The German company's main product, Deraphan©, is a combination of two clinically validated products that act on well-documented pharmacological pathways in the field of neuropsychiatry. The symptoms that Exciva aims to address are the Behavioral and Psychological Symptoms in Demented patients (BPSD), which appear in clusters with aging and are particularly prevalent in Alzheimer's disease. The company was founded by Hans Moebius and the CEOs are Bespalov Anton and François Conquet. | Hoofd Techniek/Wetenschap/O&O | 01-04-2020 | - |
Loopbaan van Hans Moebius
Eerdere bekende functies van Hans Moebius
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
ATHIRA PHARMA, INC. | Hoofd Techniek/Wetenschap/O&O | 01-04-2019 | 05-01-2024 |
Exciva GmbH
Exciva GmbH Miscellaneous Commercial ServicesCommercial Services Exciva GmbH is a clinical stage biopharmaceutical company located in Heidelberg, Germany. Exciva is focused on delivering an innovative treatment to address symptoms of Alzheimer's patients. The German company's main product, Deraphan©, is a combination of two clinically validated products that act on well-documented pharmacological pathways in the field of neuropsychiatry. The symptoms that Exciva aims to address are the Behavioral and Psychological Symptoms in Demented patients (BPSD), which appear in clusters with aging and are particularly prevalent in Alzheimer's disease. The company was founded by Hans Moebius and the CEOs are Bespalov Anton and François Conquet. | Algemeen Directeur | 01-01-2016 | 01-01-2019 |
Hoofd Techniek/Wetenschap/O&O | 01-01-2016 | 01-01-2019 | |
Oprichter | 01-01-2016 | 01-01-2019 | |
Rodin Therapeutics, Inc.
Rodin Therapeutics, Inc. BiotechnologyHealth Technology Rodin Therapeutics, Inc. develops first in class therapeutics for cognitive disorders. The company was founded by Bruce Booth in 2013 and is headquartered in Cambridge, MA. | Hoofd Techniek/Wetenschap/O&O | 01-12-2016 | 01-04-2018 |
Chase Pharmaceuticals Corp.
Chase Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Chase Pharmaceuticals Corp. develops novel medications for the treatment of Alzheimer’s disease. It focuses on pharmaceuticals for Alzheimer type dementia, which include oral medications such as its lead product, CPC-201, as well as CPC 252 for transdermal administration. The company was founded by Thomas N. Chase and Kathleen Clarence-Smith in 2007 and is headquartered in Washington, DC. | Hoofd Techniek/Wetenschap/O&O | - | 01-01-2016 |
Opleiding van Hans Moebius
Ruprecht-Karls-Universität Heidelberg | Doctorate Degree |
Technische Universität Kaiserslautern | Undergraduate Degree |
Statistieken
Internationaal
Verenigde Staten | 4 |
Duitsland | 4 |
Operationeel
Chief Tech/Sci/R&D Officer | 5 |
Chief Executive Officer | 1 |
Founder | 1 |
Sectoraal
Health Technology | 4 |
Consumer Services | 3 |
Commercial Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
ATHIRA PHARMA, INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
Exciva GmbH
Exciva GmbH Miscellaneous Commercial ServicesCommercial Services Exciva GmbH is a clinical stage biopharmaceutical company located in Heidelberg, Germany. Exciva is focused on delivering an innovative treatment to address symptoms of Alzheimer's patients. The German company's main product, Deraphan©, is a combination of two clinically validated products that act on well-documented pharmacological pathways in the field of neuropsychiatry. The symptoms that Exciva aims to address are the Behavioral and Psychological Symptoms in Demented patients (BPSD), which appear in clusters with aging and are particularly prevalent in Alzheimer's disease. The company was founded by Hans Moebius and the CEOs are Bespalov Anton and François Conquet. | Commercial Services |
Rodin Therapeutics, Inc.
Rodin Therapeutics, Inc. BiotechnologyHealth Technology Rodin Therapeutics, Inc. develops first in class therapeutics for cognitive disorders. The company was founded by Bruce Booth in 2013 and is headquartered in Cambridge, MA. | Health Technology |
Chase Pharmaceuticals Corp.
Chase Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Chase Pharmaceuticals Corp. develops novel medications for the treatment of Alzheimer’s disease. It focuses on pharmaceuticals for Alzheimer type dementia, which include oral medications such as its lead product, CPC-201, as well as CPC 252 for transdermal administration. The company was founded by Thomas N. Chase and Kathleen Clarence-Smith in 2007 and is headquartered in Washington, DC. | Health Technology |
- Beurs
- Insiders
- Hans Moebius
- Ervaring